Research programme: haemophilia A cell therapy - Sernova

Drug Profile

Research programme: haemophilia A cell therapy - Sernova

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator Sernova Corp
  • Class Cell therapies
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Haemophilia A; Type 1 diabetes mellitus

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 01 Nov 2015 Sernova enters into collaboration with University Hospital of Wurzburg, Integrierte Management Systeme, Universita del Piemonte Orientale Amedeo Avogadro, Loughborough University and GABO:mi to develop a haemophilia A cell therapy
  • 23 Apr 2015 Sernova receives patent allowance for Cell Pouch™ technology in USA
  • 14 May 2014 Sernova receives patent allowance for Cell Pouch™ and therapeutic cell transplantation technologies in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top